MXPA98009706A - Methods to increase the synthesis of oxide nitr - Google Patents
Methods to increase the synthesis of oxide nitrInfo
- Publication number
- MXPA98009706A MXPA98009706A MXPA/A/1998/009706A MX9809706A MXPA98009706A MX PA98009706 A MXPA98009706 A MX PA98009706A MX 9809706 A MX9809706 A MX 9809706A MX PA98009706 A MXPA98009706 A MX PA98009706A
- Authority
- MX
- Mexico
- Prior art keywords
- phenyl
- formula
- compound
- alkyl
- cells
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title claims description 5
- 238000003786 synthesis reaction Methods 0.000 title claims description 5
- 230000002194 synthesizing Effects 0.000 title claims description 5
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims abstract description 85
- 150000001875 compounds Chemical class 0.000 claims abstract description 35
- 239000011780 sodium chloride Substances 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- 210000002889 Endothelial Cells Anatomy 0.000 claims abstract description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 12
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 8
- 125000001309 chloro group Chemical group Cl* 0.000 claims abstract description 6
- 239000012453 solvate Substances 0.000 claims abstract description 6
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims abstract description 5
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims abstract description 4
- 239000001257 hydrogen Substances 0.000 claims abstract description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 4
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 7
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 230000004962 physiological condition Effects 0.000 claims description 4
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- WCLJTEXCGGSJJN-UHFFFAOYSA-N 4-(2-piperidin-1-ylethoxy)benzaldehyde Chemical compound C1=CC(C=O)=CC=C1OCCN1CCCCC1 WCLJTEXCGGSJJN-UHFFFAOYSA-N 0.000 claims 1
- TUCNEACPLKLKNU-UHFFFAOYSA-N ethanone Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 claims 1
- 230000001965 increased Effects 0.000 abstract description 12
- -1 R 1 is R Chemical group 0.000 abstract description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 description 21
- 210000004027 cells Anatomy 0.000 description 17
- 230000003511 endothelial Effects 0.000 description 17
- 239000004480 active ingredient Substances 0.000 description 15
- 238000009472 formulation Methods 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N Cyclic guanosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 9
- 102100000871 NOS3 Human genes 0.000 description 8
- 101700006637 NOS3 Proteins 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 238000007792 addition Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- 206010012601 Diabetes mellitus Diseases 0.000 description 5
- 235000014852 L-arginine Nutrition 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 230000001419 dependent Effects 0.000 description 5
- 230000001575 pathological Effects 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drugs Drugs 0.000 description 4
- 230000001105 regulatory Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000005711 Benzoic acid Substances 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 3
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 3
- 229940083618 Sodium Nitroprusside Drugs 0.000 description 3
- 208000010110 Spontaneous Platelet Aggregation Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- GIRZNGMZUXTPTL-UHFFFAOYSA-N disodium;iron(3+);nitroxyl;pentacyanide;dihydrate Chemical compound O.O.[Na+].[Na+].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].O=N GIRZNGMZUXTPTL-UHFFFAOYSA-N 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 150000003840 hydrochlorides Chemical class 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000002459 sustained Effects 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- SNIOPGDIGTZGOP-UHFFFAOYSA-N 1,2,3-propanetrioltrinitrate Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 description 2
- 102000014469 EC 4.6.1.2 Human genes 0.000 description 2
- 108010078321 EC 4.6.1.2 Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 229960002743 Glutamine Drugs 0.000 description 2
- 239000012593 Hanks’ Balanced Salt Solution Substances 0.000 description 2
- 210000004969 Inflammatory Cells Anatomy 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 210000000329 Myocytes, Smooth Muscle Anatomy 0.000 description 2
- 229940014995 Nitroglycerin Drugs 0.000 description 2
- 239000000006 Nitroglycerin Substances 0.000 description 2
- 229940049954 Penicillin Drugs 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229960004622 Raloxifene Drugs 0.000 description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N Raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
- 229960002119 Raloxifene Hydrochloride Drugs 0.000 description 2
- 229960005322 Streptomycin Drugs 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- 206010047163 Vasospasm Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 229960000626 benzylpenicillin Drugs 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 201000008739 coronary artery disease Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000000968 intestinal Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 230000003000 nontoxic Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- BKXVVCILCIUCLG-UHFFFAOYSA-N raloxifene hydrochloride Chemical compound [H+].[Cl-].C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 BKXVVCILCIUCLG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000025033 vasoconstriction Effects 0.000 description 2
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-M 2,3-dinitrobenzoate Chemical compound [O-]C(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-M 0.000 description 1
- URZHQOCYXDNFGN-UHFFFAOYSA-N 2,4,6-trimethyl-2,4,6-tris(3,3,3-trifluoropropyl)-1,3,5,2,4,6-trioxatrisilinane Chemical compound FC(F)(F)CC[Si]1(C)O[Si](C)(CCC(F)(F)F)O[Si](C)(CCC(F)(F)F)O1 URZHQOCYXDNFGN-UHFFFAOYSA-N 0.000 description 1
- IKCLCGXPQILATA-UHFFFAOYSA-M 2-chlorobenzoate Chemical compound [O-]C(=O)C1=CC=CC=C1Cl IKCLCGXPQILATA-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- PXACTUVBBMDKRW-UHFFFAOYSA-M 4-bromobenzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-M 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- 229960004373 Acetylcholine Drugs 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-M Acetylsalicylate Chemical compound CC(=O)OC1=CC=CC=C1C([O-])=O BSYNRYMUTXBXSQ-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 229940072107 Ascorbate Drugs 0.000 description 1
- 108060001001 BRK1 Proteins 0.000 description 1
- FCEHBMOGCRZNNI-UHFFFAOYSA-N Benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 1
- 210000001772 Blood Platelets Anatomy 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N Bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 229960005069 Calcium Drugs 0.000 description 1
- 229960003563 Calcium Carbonate Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 210000003169 Central Nervous System Anatomy 0.000 description 1
- 208000004981 Coronary Disease Diseases 0.000 description 1
- 210000004351 Coronary Vessels Anatomy 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- 229960005309 Estradiol Drugs 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229960002897 Heparin Drugs 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 208000009576 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100011311 KNG1 Human genes 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- MRAUNPAHJZDYCK-BYPYZUCNSA-N L-nitroarginine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O MRAUNPAHJZDYCK-BYPYZUCNSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 208000010125 Myocardial Infarction Diseases 0.000 description 1
- QIAFMBKCNZACKA-UHFFFAOYSA-M N-benzoylglycinate Chemical compound [O-]C(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-M 0.000 description 1
- XCRBXWCUXJNEFX-UHFFFAOYSA-N Peroxybenzoic acid Chemical compound OOC(=O)C1=CC=CC=C1 XCRBXWCUXJNEFX-UHFFFAOYSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 229960003531 Phenolsulfonphthalein Drugs 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N Phenylpropanoic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J Pyrophosphate Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- HWKQNAWCHQMZHK-UHFFFAOYSA-N Trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 description 1
- 210000003606 Umbilical Veins Anatomy 0.000 description 1
- HMGCGUWFPZVPEK-UHFFFAOYSA-M [O-]C(=O)C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=C1 Chemical compound [O-]C(=O)C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=C1 HMGCGUWFPZVPEK-UHFFFAOYSA-M 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000274 adsorptive Effects 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229940027983 antiseptics and disinfectants Quaternary ammonium compounds Drugs 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 201000001320 atherosclerosis Diseases 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000003710 calcium ionophore Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M caprate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- 125000004432 carbon atoms Chemical group C* 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000271 cardiovascular Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000012592 cell culture supplement Substances 0.000 description 1
- 230000002490 cerebral Effects 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- JOYKCMAPFCSKNO-UHFFFAOYSA-N chloro benzenesulfonate Chemical compound ClOS(=O)(=O)C1=CC=CC=C1 JOYKCMAPFCSKNO-UHFFFAOYSA-N 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 230000002939 deleterious Effects 0.000 description 1
- 150000005195 diethylbenzenes Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 230000000916 dilatatory Effects 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003628 erosive Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- WTDFFADXONGQOM-UHFFFAOYSA-N formaldehyde;hydrochloride Chemical compound Cl.O=C WTDFFADXONGQOM-UHFFFAOYSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- TVZISJTYELEYPI-UHFFFAOYSA-N hypodiphosphoric acid Chemical class OP(O)(=O)P(O)(O)=O TVZISJTYELEYPI-UHFFFAOYSA-N 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000000302 ischemic Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-M isethionate Chemical compound OCCS([O-])(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-M 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-M isobutyrate Chemical compound CC(C)C([O-])=O KQNPFQTWMSNSAP-UHFFFAOYSA-M 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 210000002569 neurons Anatomy 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N o-xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-L oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-M phenylacetate Chemical compound [O-]C(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-M 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- 229960004723 phenylbutyrate Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L phosphate Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L propanedioate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M pyridine-4-carboxylate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N rac-1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 230000000391 smoking Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M stearate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 201000010874 syndrome Diseases 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 150000003577 thiophenes Chemical class 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Abstract
The present invention provides methods for increasing the concentration of nitric oxide (NO) in vascular endothelial cells, which comprises administering a compound of formula (I), wherein: R is hydrogen, -OH, -O (C1-C4 alkyl) , -OCO (C 1 -C 4 alkyl), or -OCOAr, where Ar is an optionally substituted phenyl or phenyl, R 1 is R, -Cl or -F, R 2 is 1-pyrrolidinyl, 1-piperidinyl or 1-hexamethyleneimino; a salt or solvate thereof pharmaceutically acceptable
Description
METHODS TO INCREASE THE SYNTHESIS OF NITRIC OXIDE
FIELD OF THE INVENTION
The present invention relates to the fields of organic chemistry and pharmacology and provides compounds and methods for increasing the synthesis of endothelial nitric oxide (NO), particularly in vascular endothelial cells.
BACKGROUND OF THE INVENTION
Nitric oxide is a regulatory molecule that plays a vital role in the normal physiology of the cardiovascular, intestinal, central nervous and immune systems. Nitric oxide is synthesized from L-arginine by a family of enzymes known as NO synthase (NOS). Particularly related to the present invention is calcium-dependent NOS produced in vascular endothelial cells, known as eNOS. Recently, there have been numerous studies that have linked the regulation of the eNOS gene with the hormone estrogen. It has been shown that estrogen over-regulates the production of eNOS m-RNA and by
REF: 28604 consequently, the synthesis of eNOS in endothelial cells. This increase in the amount of eNOS allows endothelial cells to produce more NO in response to the appropriate stimulus in the vascular system. In the vasculature, the NO endothelial derivative has several actions, among which are the inhibition of platelet aggregation, the adhesion of inflammatory cells and the proliferation of smooth muscle cells. The endothelial derived NO is an important regulator of vascular tone. . Flow-dependent dilation, a commonly used index of endothelial functions, is largely mediated by NO. The mechanism for regulating vascular tone by NO is initiated by stimuli, such as acetylcholine, bradykinin, shear stress, etc., on the endothelial lining cells. Endothelial cells respond by producing NO from L-arginine by eNOS. The NO produced leaves the endothelial cells and stimulates the activity of the guanylate cyclase in the adjacent smooth muscle cells. The activation of guanylate cyclase increases the level of cGMP and causes the smooth cells to relax, thus dilating the vessel and increasing blood flow. For other information, see: Moneada et a l. , New In g. J. Med. , 329, pp. 2002-2012 (1993), and Vallance, et al. L. , J. Royl. Coi l. Phys i ci a n London, 28, pp. 209-219 (1994). The generation of reduced endothelial NO can lead to altered vasodilation, abnormal vasospasm, increased platelet aggregation, and increased adhesion and infiltration of inflammatory cells. Altered endothelial NO and endothelial function are associated with the risk factors for coronary artery disease, including smoking, hypercholesterolemia, homocysteineuria, and diabetes. The alteration of the activities modulated by NO in the coronary arteries can contribute to worsen the coronary syndrome that gives rise to myocardial infarction. The alteration of the endothelial NO system and its resultant vasoconstriction have been implicated in the exacerbation of damage to neurons in cerebral ischemic events, such as stroke. Additionally, recent studies indicate that endothelial NO mediates vascular sensitivity to insulin, thus increased NO production may be useful in treating vascular effects of diabetes. In general, there is a large body of evidence, both experimental and clinical, which indicates that increasing NO concentrations in the vasculature is beneficial in many pathological conditions, such as diabetes, stroke, erosions and hypertension. The current therapy for increasing NO concentrations in the vasculature has been either to administer high doses of L-arginine (the eNOS substrate) or compounds such as nitroglycerin or sodium nitroprusside, which metabolically release NO. Although, these therapies can be effective, each one has shown undesirable side effects. Additionally, therapies suffer from their inability to maintain sustained release, from NO, due to their rapid elimination from the body. It would be of great benefit if a new therapy were available to increase NO concentrations in the vasculature.
BRIEF DESCRIPTION OF THE INVENTION
The present invention provides methods for increasing the endothelial derivative of NO which comprises administering to a human being in need thereof an effective amount of a compound of the formula I
e-n wherein: R is hydrogen, -OH, -O (C1-C4 alkyl), -OCO (C-alkyl) -C), or -OCOAr, where Ar is a phenyl or optionally substituted phenyl; Ri is R, -Cl or -F; R 2 is 1-pyrrolidinyl, 1-piperidinyl or 1-h'exametiminimino; or a pharmaceutically acceptable salt or solvate thereof.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to the discovery that a select group of 2-aryl-benzo [b] thiophenes, the compounds of formula I, are useful for increasing the concentration of eNOS and
NO of the endothelial derivative. The general terms used in the description of the compounds described herein carry their usual meanings. For example, "C?-C 4 alkyl" refers to straight or branched α-linear chains of 1 to 4 carbon atoms including methyl, ethyl, propyl, isopropyl, n-butyl and the like. The term "substituted phenyl" refers to a phenyl group which has one or two substituents selected from the group consisting of C-C4 alkyl, C? -C4 alkoxy, hydroxy, nitro, chloro, fluoro or tri (chloro) or fluoro) met ilo. "0 (C 1 -C 4 alkyl)" refers to a C 1 -C 4 alkyl group attached via an oxygen bridge such as methoxy, ethoxy, n-propoxy, iso-propoxy and the like. The term "pharmaceutically acceptable salt" refers to any acid or base addition salts that are known to be non-toxic and are commonly used in the pharmaceutical literature. Commonly used acid addition salts include: inorganic salts formed by the addition of sulfuric acid, nitric acid, hydrochloric acid, hydrobromic acid, phosphoric acid, phosphorous acid and the like; or organic salts formed by the addition of acetic acid, formic acid, benzoic acid, citric acid, methanesulfonic acid and the like. Commonly used basic addition salts would include salts formed by alkali or alkaline earth metal hydroxides, ammonium hydroxide, alkyl or aromatic amines and the like. A preferred salt of this invention would be the hydrochloride salt. The phrase "inhibit a physiological condition associated with a lack of or need for nitric oxide (NO)" includes prohibiting, preventing, restricting, and decreasing, stopping, or reversing progression, severity, or a symptom or effect resulting from the physiological condition. . Such physiological conditions include. those mentioned in this application, such as the aggregation of pathological platelets, pathological vasoconstriction, vascular effects of diabetes, stroke, atherosclerosis and abnormal vasospasm.
The term "solvate" represents an aggregate comprising one or more molecules of a solute, such as a compound of formula I, with one or more molecules of a suitable solvent. Raloxifene hydrochloride, which is a preferred embodiment of this invention, is a compound of formula I, wherein R and Ri each are hydroxyl; R2 is 1-piperidinyl; and it's like its hydrochloride salt. Raloxifene is named: [2- (4-hydroxyphenyl) -6-hydroxybenzo [b] thien-3-yl] [4- [2- (1-piperidenyl) ethoxy] phenyl] methanone hydrochloride. Generally, at least one compound of formula I is formulated with common excipients, diluents or carriers and compressed into tablets, or formulated as elixirs or solutions for convenient oral administration, or administered intramuscularly or intravenously. The compounds can be administered transdermally, and can be formulated as sustained release dosage forms and the like. The compounds used in the methods of the present invention can be made in accordance with established procedures, such as those detailed in U.S. Patent Nos. 4., 133,814, 4,418,068, 4,380,635 and 5,393,763, all of which are incorporated by reference herein. In general, the process starts with a benzo [b] thiophene having a 6-hydroxyl group and a 2- (4-hydroxyphenyl) group. The initial compound is protected, acylated and deprotected to form the compounds of formula I. Examples of the preparation of such compounds are provided in the U.S. Patents discussed above. The compounds used in the methods of this invention form pharmaceutically acceptable acid and base addition salts with a wide variety of organic and inorganic acids and include the physiologically acceptable salts that are frequently used in pharmaceutical chemistry. Such salts are also part of this invention. Typical inorganic acids used to form salts include hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, phosphoric, hypophosphoric acids and the like. Salts derived from organic acids, such as mono- and dicarboxylic aliphatic acids, f.enyl-substituted alkanoic acids, hydroxyalkanoic and hydroxyalkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids can also be used. Such pharmaceutically acceptable salts of this form include acetate, phenylacetate, trifluoroacetate, acrylate, ascorbate, benzoate, chlorobenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, methybenzoate, o-acetoxybenzoate, naphthalene-2-benzoate, bromide, isobutyrate, phenylbutyrate, ß-hydroxybutyl, but in-1, 4-dioate, hexin-1,4-dioate, caprate, caprylate, chloride, cinnamate, citrate, formate, fumarate, glycolate, heptanoate, hippurate, lactate, malate, maleate, hydroxyaleate, malonate, mandelate, mesylate, nicotinate, isonicotinate, nitrate, oxalate, fatalate, teraphthalate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, propiolate, propionate, phenylpropionate, salicylate, sebacate, succinate, suberate, sulfate, bisulfate, pyrosulfate, sulfite , bisulfite, sulfonate, benzene sulfonate, p-bromophenylsulphonate, chlorobenzenesulfonate, ethanesulphonate, 2-hydroxyethane sulfonate, methanesulphonate, naphthalene-1-sulfonate, naphthalene-2-sulfonat or, p-toluenesulfonate, xylene sulphonate, tartrate and the like. A preferred salt is the hydrochloride salt. The pharmaceutically acceptable acid addition salts are typically formed by reacting a compound of the formula I with an equimolar or excess amount of acid. The reagents are generally combined in a m.utuous solvent such as diethyl ether or benzene. The salt is usually precipitated from the solution within about one hour to 10 days and can be isolated by filtration or the solvent can be washed by conventional means. As used herein, the term "effective amount" means an amount of the compound of formula I that is capable of increasing the NO concentration of the endothelial derivative in a human being in need of such treatment. Humans in need of treatment would include, but are not limited to, those suffering from inappropriate v-asoconst ricción or platelet aggregation due to damage of the endothelial NO regulatory pathway by the risk factors of coronary heart disease, diabetes , and similar. As prevented in this invention, a compound of formula I would be useful in inhibiting, improving, reducing, limiting or preventing pathological sequelae due to damage of the endothelial NO regulatory pathway. The specific dose of a compound administered according to this invention will, of course, be determined by the surrounding circumstances particular to the case including, for example, the compound administered, the route of administration, the state in which the patient is, and the pathological condition that is treated. A typical daily dose will contain a non-toxic dose level from about 0.1 mg to about 1000 mg / day of a compound of the present invention, and more particularly will be from about 15 mg to about 80 mg '/ day from one to three times each day or as often as necessary for its effectiveness. In addition, the compounds of the formula I can be used at the same time or sequentially with other agents that interact with the endothelial NO pathway, for example, nitroglycerin, sodium nitroprusside, L-arginine and the like. By "pharmaceutically acceptable formulation" it is meant that the carrier, diluent, excipients and salt must be compatible with the active ingredient (a compound of formula I) of the formulation, and not be deleterious to the container of the same. The pharmaceutical formulations can be prepared by methods known in the art.
For example, the compounds of this invention can be formulated with common excipients, diluents or carriers and formed into tablets, capsules and the like. Examples of excipients, diluents and carriers that are suitable for such formulations include the following: relievers and expanders such as starch, sugars, mannitol and silicic derivatives; binding agents such as carboxymethylcellulose and other cellulose derivatives, alginates, gelatin and polyvinylpyrrolidone; wetting agents such as glycerol; disintegrating agents such as agar agar, calcium carbonate and sodium bicarbonate; agents for delayed dissolution such as paraffin; resorption accelerators such as quaternary ammonium compounds; active surface agents such as alcohol. cetyl, glyceryl monostearate; adsorptive carriers such as kaolin and bentonite; and lubricants such as talc, calcium and magnesium stearate and solid polyethylene glycols. The final pharmaceutical forms can be: pills, tablets, powders, pills, syrups, aerosols, sachets, seals, elixirs, suspensions, emulsions, ointments, suppositories, sterile injectable solutions, or sterile packaged powders, depending on the type of excipient used. Additionally, the compounds of this invention are very suitable for formulation as sustained release dosage forms. The formulations can also be constituted in such a way that they release only the active ingredient or preferably in a particular section of the intestinal tract, possibly for a period of time. Such formulations would involve coatings, envelopes or protective matrices that can be made from polymeric substances or waxes. The following formulations are given for purposes of illustration and are not intended to be limiting in any way. The total active ingredients in such formulations comprise from 0.1% to 99.9% by weight of the formulation. The term "active ingredient" means a compound of the formula I or a salt or solvate thereof.
Formulations
Formulation 1: Gelatin Capsules Hard gelatin capsules are prepared using the following:
Ingredient Quantity (mg / capsule)
Active ingredient 0. 1 - - 1 0 0 0
Starch, NF 0 - - 6 5 0
Flowable starch powder 0 - - 6 5 0
Silicone fluid 350 centistokes 0 - 1 5
The ingredients are mixed, passed through a 45 U.S. mesh screen. and they are filled into hard gelatin capsules. The above formulations can be changed in accordance with the reasonable variations provided. A tablet formulation is prepared by using the following ingredients:
Formulation 2: Tablets
Ingredient Quantity (mg / tablet
Active ingredient 2.5 1000 Microcrystalline cellulose 200 650 Gaseous silicon dioxide 10 650 Acid stearate 5 15 The components are mixed and compressed to form tablets. Alternatively, each of the tablets containing 2.5-1000 mg of active ingredient is manufactured as follows:
Formulation 3: Tablets
Ingredient "Amount (mg / tablet
Active ingredient 25 - 1000
Starch 45 Microcrystalline cellulose 35 Polyvinylpyrrolidone 4 (as 10% solution in water) Sodium carboxymethylcellulose 4.5 Magnesium stearate 0.5 Talcum 1
The active ingredient, starch and cellulose are passed through a No. 45 mesh U.S. and mixes completely. The polyvinylpyrrolidone solution is mixed with the resultant powders which are then passed through a No. 14 U.S. mesh screen. The granules thus produced are dried at 50 ° -60 ° C and passed through a No. 18 U.S. mesh screen. Sodium carboxymethyl starch, magnesium stearate and talc are passed through a No. 60 U.S. mesh screen, then added to the granules which, after mixing, are compressed in a compressor machine to produce tablets. Each of the suspensions containing 0.1 - 1000 mg of medication per 5 ml of dose is made as follows:
Formulation 4: Suspensions
Ingredient Quantity (mg / 5 ml)
Active ingredient 0.1 - 1000 mg Sodium carboxymethylcellulose 50 mg Syrup 1.25 mg Benzoic acid solution 0.10 ml Flavor c. v. C color . V Purified water for 5 ml
The medication is passed through a No. 45 mesh U.S. and it is mixed with sodium carboxymethyl cellulose and syrup to form a soft paste. The benzoic acid solution, flavor and color are diluted with some of the water and added, with stirring. Sufficient water is then added to produce the required volume. An aerosol solution is prepared containing the following ingredients:
Formulation 5: Aerosol
Ingredient Amount (% by weight)
Active ingredient 0.25 Ethanol 25.75 Propellant 22 (Clorodi f luoromethane) 70.00
The active ingredient is mixed with ethanol and the mixture is added to a portion of the propellant 22, cooled to 30 ° C, and transferred to a filling device. The required amount is then fed * to a stainless steel vessel and diluted with the remaining propellant. The valve units are adjusted to the container.
Suppositories are prepared as follows Formulation 6: Suppositories
Ingredient Quantity (mg / suppository)
Active ingredient 250 Saturated fatty acid glycerides 2,000
The active ingredient is passed through a No. 60 mesh U.S. and is suspended in the saturated fatty acid glycerides previously fused using the minimum necessary heat. The mixture is then emptied into a suppository mold of 2 nd.minal capacity and allowed to cool. An intravenous formulation is prepared as follows:
Formulation 7: Intravenous solution
Ingredient Amount
Active ingredient 50 mg Isotonic saline solution 1 000 ml The solution of the above ingredients is administered intravenously to a patient at a rate of approximately 1 ml per minute.
TEST PROCEDURE As evidence of the utility of the compounds of the present invention for raising the concentration of NO in the endothelial tissue, the following test system is used.
Cell Cultures: Single-donor, cryopreserved human umbilical vein endothelial cells (HUVEC) were purchased from Clonetics Corporation, San Diego CA. These cells are defined by Clonetics to be the 1st (first-pass cells). The cells are stored in liquid nitrogen and fresh aliquots are taken for each experiment. The cells are thawed and placed in a T-75 flask with 75 ml of medium. For all HUVEC cultures, all glassware (Corning) is coated with 0.2% gelatin (Sigma Chemical Co.) in M199 medium (Gibco) for twenty minutes at 37 ° C. Cells were cultured in M199 free phenol red, with 10% fetal bovine serum (Gibco), 50 ug / ml endothelial cell culture supplement (Collaborative Biochemical Products, Bedford MA), 100 ug / ml heparin pig (Gibco, 10 units / ml of penicillin, 10 ug / ml of streptomycin, and 0.2 mM of L-glutamine at 37 ° C and 5% of C02.) When the cells of the 2nd crop reach 70-90 % confluence, divided 1: 3 over T-75 flasks coated with gelatin with 15 ml of medium to produce 3rd crop cells, after which these cultures reached 70-90% confluence, typically 3-4 days, these 4th crop cells were divided into 1: 3 on 12-well plates coated in 1 ml of medium.All experiments were conducted with these cells from the fourth step.After 72 hours, the cells were confluent and the treatments were initiated with drug The above medium is removed by aspiration and 1 ml of medium is added to test the drug with the drug (15% gelatinized horse serum (GemJni Bioproducts, Calabasas CA, 10 units / ml penicillin, 10 ug / ml streptomycin, and 0.2 mM L-glutamine). Stock solutions of the test compounds of formula I or 17-β-est radiol were prepared in 10 mM in DMSO. The cells were treated with the drug for 48 hours at 37 ° C.
Induction of cGMP Nitric Oxide Dependent Three plates (one experimental) are removed from the incubator and placed on a paper towel to prevent cooling. One plate at a time, the medium is removed, and 1 ml of warm HBSS is added
(Gibco) This is removed and replaced with 0.5 ml of balance buffer +/- 200 uL of L-NAME
(N-nitro-L-arginine methyl ester, Sigma). The equilibrium buffer consists of HBSS, 10 mM HEPES, 1.2 mM CaCl2, 0.6 mM MgSO4 and 0.5 mM isobutyl ilmet il-xanthine (IBMX) and 10 uM L-arginine, which is added freshly prepared to each stock solution. I.BMX is prepared as a 200 mM stock solution in DMSO at 37 ° C. The cells are allowed to equilibrate for 30 minutes at 37 ° C in 5% C02. After incubation, 0.5 ml of "stimulation" buffer with stimulant is added for 10 minutes. The stimulation buffer for the controls consists of the equilibrium buffer plus a designated stimulant, which are: 1) negative control, 2) positive control, sodium nitroprusside 1 mM (Sigma), 3) 1 uM of A-23187 ( calcium ionophore) (Sigma), 4) 1 uM of A-23187 and 200 uM of L-NAME (This control group demonstrates that the observed effects (increased in cGMP) in this assay are due solely to the NO 'produced in the endothelial cells.) Test cells treated with the compounds of formula I are stimulated with 1 uM of A-23187. After 10 minutes, the buffers are removed and 200 ul of 0.01 N HCl are added, and the cGMP is extracted by rocking the cells for 30 minutes at 4 ° C. Each aliquot of 200 ul is placed in a tube containing 2 ul of 1 N NaOH. Samples are frozen at -20 ° C for storage. To each well of the plate, 250 ul of 0.5% SDS in 0.1 N NaOH are added to solubilize the bound cells. The plates were wrapped in plastic wrap and frozen at -20 ° C for a subsequent protein assay by the BCA method (Pierce Chemical Co.). (The total average amount of protein in mg is determined for all wells in an experiment and used to normalize the cGMP content.) The cGMP content is determined by enzyme immunoassay (Amersham Co, RPN.226) according to the manufacturer's instructions for the acetylation protocol. Assays are made according to the instructions, except that the acetylation of the 200 ul samples was with 20 ul of reagent instead of 100 ul for 1 ml samples. The assays were quantified in a 450 nM thermomax spectrophotometer.
The positive control of 17-ß-est radio! demonstrates the expected increase in the amount of NO-dependent cGMP. It is discovered that the compounds of formula I increase the concentration of NO and induce cGMP in these endothelial cells. In Table 1, the increase in NO-dependent cGMP for raloxifene hydrochloride is shown.
Table 1 Compound Concentration3 Level of cGMPb
Control 1.30 Raloxifene 0.1 2.55 * 1..0 2.65 * a pM / mL b pM / mg protein \ P > - 01 It is noted that in relation to this date, the best method known by the applicant to carry out the aforementioned invention, is the conventional one for the manufacture of the objects or products to which it refers. Having described the invention as above, property is claimed as contained in the following:
Claims (4)
- The use of a compound of the formula characterized in that: R is hydrogen, -OH, -O (Cj.-C4 alkyl), -OCO (C? -C4 alkyl), or -OCOAr, where Ar is a phenyl or optionally substituted phenyl; Ri is R, -Cl or -F; R2 is 1-pyrrolidinyl, 1-piperidinyl or 1-hexamethyleneimino; or a pharmaceutically acceptable salt or solvate thereof, used in the preparation of a β-cation to increase the synthesis of nitric oxide (NO) in vascular endothelial cells in a human.
- 2. The use according to claim 1, characterized in that the compound of formula I is [2- (4-hydroxyphenyl) -6-hydroxybenzo [b] thien-3-yl] [4- [2- (1-hydrochloride. -piperidinyl) ethoxy] phenyl] ethanone.
- 3. The use of a compound of the formula (I) characterized in that: R is hydrogen, -OH, -O (C? -C4 alkyl), -OCO (d-C4 alkyl), or -OCOAr, where Ar is a phenyl or optionally substituted phenyl; Ri is R, -Cl or -F; R2 is 1-pyrrolidinyl, 1-piperidinyl or 1-hexamethyleneimino; or a pharmaceutically acceptable salt or solvate thereof used in the preparation of a medicament for inhibiting a physiological condition associated with a lack of or need for, nitric oxide (NO).
- 4. The use according to claim 3, characterized in that the compound of the formula I is [2- (4-hydroxy phenyl) -6-hydroxy-benzo [b] thien-3-yl] [4- [2- (l-piperidinyl) ethoxy] phenyl] methanone.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US018071 | 1996-05-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA98009706A true MXPA98009706A (en) | 1999-09-20 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR19980702079A (en) | Methods of Inhibiting Cell-Cell Adhesion | |
US6096781A (en) | 2-arylbenzo[B]thiophenes useful for the treatment of estrogen deprivation syndrome | |
AU716064B2 (en) | Methods of increasing nitric oxide synthesis | |
EP0920863B1 (en) | The use of 2-Aryl-3-aroylbenzo(b)thiophenes for the treatment of estrogen deprivation syndrome | |
EA000767B1 (en) | Benzothiophenes, formulations containing same, and methods | |
US5962698A (en) | Benzothiophene compounds, and uses and formulations thereof | |
MXPA98009706A (en) | Methods to increase the synthesis of oxide nitr | |
US6060488A (en) | Benzothiophenes for treating estrogen deficiency | |
EA001003B1 (en) | Method of inhibiting plasminogen activator inhibitor 1 | |
AU741882B2 (en) | Methods for lowering platelet counts | |
KR20010052947A (en) | Methods for Reducing Levels of Homocysteine and C-Reactive Protein | |
JPH08269045A (en) | 3-benzyl-benzothiophene compound | |
CZ375098A3 (en) | Pharmaceutical preparation for increasing synthesis of endothelial dinitrogen pentaoxide | |
MXPA98002759A (en) | Methods to inhibit plasminog activator 1 inhibitor | |
MXPA00004482A (en) | 2-arylbenzo[b]thiophenes useful for the treatment of estrogen deprivation syndrome | |
MXPA00011283A (en) | Methods for reducing levels of homocysteine and c-reactive protein | |
MXPA98006763A (en) | Benzotiophenes and formulations that contain them |